The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform

V Jokubaitis, T Spelman, J Lechner-Scott, Michael Barnett, C Shaw, Steve Vucic, Danny Liew, H Butzkueven, Mark Slee

    Research output: Contribution to journalArticle

    30 Citations (Scopus)

    Abstract

    Objective: To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. Methods: Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation, persistence, predictors of treatment discontinuation and switch rates. Multivariable survival analyses were used to compare treatment persistence between drugs and to identify predictors of treatment discontinuation. Results: 1113 RRMS patients were studied. Patients persisted on their first disease-modifying therapy (DMT) for a median of 2.5 years. Treatment persistence on GA was shorter than on all IFNβ products (p<0.03). Younger age at treatment initiation and higher EDSS were predictive of DMT discontinuation. Patients persisted on subsequent DMTs, for 2.3 years. Patients receiving natalizumab (NAT) as a subsequent DMT persisted longer on treatment than those on IFNβ or GA (p<0.000). The primary reason for treatment discontinuation for any drug class was poor tolerability. Annualised switch or cessation rates were 9.5-12.5% for individual IFNβ products, 11.6% for GA and 4.4% for NAT. Conclusion: This multicentre MS cohort study is the first to directly compare treatment persistence on IFNβ and GA to NAT. We report that treatment persistence in our Australian RRMS population is short, although patients receiving IFNβ as a first DMT persisted longer on treatment than those on GA. Additionally, patients receiving NAT as a subsequent DMT were more likely to persist on treatment than those switched to IFNβ or GA. EDSS and age at DMT initiation were predictive of DMT discontinuation. Treatment intolerance was the principal reason for treatment cessation.

    Original languageEnglish
    Article numbere59694
    Pages (from-to)e59694
    Number of pages9
    JournalPLoS One
    Volume8
    Issue number3
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform'. Together they form a unique fingerprint.

  • Cite this

    Jokubaitis, V., Spelman, T., Lechner-Scott, J., Barnett, M., Shaw, C., Vucic, S., Liew, D., Butzkueven, H., & Slee, M. (2013). The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS One, 8(3), e59694. [e59694]. https://doi.org/10.1371/journal.pone.0059694